Market Analysis
Why Is Eli Lilly (LLY) Stock Up Premarket? $2.4B Biotech Acquisition
Eli Lilly shares rose in premarket trading after the company announced a $2.4 billion deal to acquire Orna Therapeutics.
Total Stories
10
News
Eli Lilly
Section
Eli Lilly
Market Analysis
Why Is Novo Nordisk Stock Down 13% Premarket? Trial Fails to Match Eli Lilly
Novo Nordisk stock plunged over 13% in premarket trading after its experimental obesity drug CagriSema failed to prove non-inferiority to Eli Lilly's tirzepatide in the REDEFINE 4 trial.
Market Analysis
Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?
Eli Lilly is reportedly close to acquiring gene editing partner Verve Therapeutics for up to $1.3 billion.
Market Analysis
Eli Lilly’s Stock Tumbles as Firm Cuts EPS Guidance Despite Strong Q1
Eli Lilly's stock dropped over 7% after announcing a lowered profit forecast, despite exceeding Q1 expectations.
Market Analysis
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs
Verge Genomics and Eli Lilly have made significant progress in their collaboration to develop ALS treatments, identifying two promising drug targets using AI technology.
Market Analysis
The Weight Loss Market Can Surge to $400 B by 2032, and these Stocks Will Rule it
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.
Best Stocks
LLY vs NVO: Which One is Likely to Become a $1T Company First
Tackling growing waistlines is expected to yield much shareholder value.
Best Stocks
Pfizer’s Stock is Down 44% YTD as Woes Continue
Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug.
Best Stocks
LLY and NOVO Report Strong Earnings But Are Vulnerable to Q4 Headwinds
Eli Lilly and Novo Nordisk continue to capitalize on unprecedented interest for weight-loss drugs, with both companies posting strong Q3 results on Thursday.
Best Stocks
421 Stocks Out of the S&P 500 Are Down Since July; These 3 Bucked the Trend
With Big Tech underperforming, some stocks enjoy double-digit gains.